Member Info for JimmyRodrigues

Sandykneesurfer

Thanks-always look forward to your posts. My sentiments exactly.

Collaborations, deals, partners should mean something. I once thought so. But now I look at financial reports. That tells you all you need to know. Separates the reality from the hot air

More published insights and business facts and less insults. We’re all grown up, mature and hopefully honourable…..not faceless trolls.

Dread to think what would have happened if the news was bad!

EBITDA profits doubled, revenue up 16%, gross profit

up from 46% to 53%. Expansion, cash, distributors…… AIM(ing) HIGH!!!

So I’m stuck with it praying for sweetbiotix or all the deals to matérialise into some meaningful revenues.

Https://www.medscape.com/viewarticle/sugar-substitutes-originally-meant-reduce-health-risk-may-2024a1000ekg?ecd=a2a

I think research is expensive and scientific and clinical validation adds commercial value (or should). Universities are not charities nor should they be treated as such. Commercial entities should fund R&D properly or agree to share a proportion of the profits they generate from the validation. Buying the ingredients, doing the mixing and not getting a slice of the cake is not particularly enticing……

As summer turns to autumn and the fall, so attention in the #DMS world moves to pending decisions from #safety agencies that will define the future of the #driver and #occupant #monitoring market. NHTSA is set to issue the #FMVSS for #impaired driving before the end of the year, to mitigate #distracted, #drowsy and #drunkdriving in the U.S. But it is Euro NCAP - For Safer Cars, Vans & Trucks that is about to really shake things up, with imminent publication of its 2026 Occupant Status Monitoring #OSM #protocols and how these feed into the 5* safety rating. Let's take a look.

Everything changes for the star ratings in 2026. We already know the framework, because that is published. For the 2023 assessment, OSM gave up to 3 points, but OEMs could game the scoring by using woeful DMS and focus on getting points elsewhere to still get a 5* rating. This drove procurement towards low cost DMS which infuriated drivers.

But for 2026, DMS and #OMS (along with vehicle assistance) go into a category called "safe driving." OMS scores 30 points, DMS 30, and assistance 40. What is new is the "balance thresholds" needed for a 5* rating. In 2026, the safe driving category needs 60 points to get 5*, but in 2027 it needs 70, and from 2028 it is 80. Sure an #OEM can "borrow" up to 5 points from "crash avoidance," but the focus shifts to scoring for OMS and DMS. This massively uprates the importance of DMS and OMS performance from 2026, which is exactly what I said would happen. Cheap DMS will come with major consequences.

Further, an OEM will have to score for both driver and occupant monitoring to secure the coveted 5* rating. Sure, we've seen dual camera systems in BMW, but that is a premium brand. How does a mass-market OEM score points for both driver and occupant monitoring within a tight budget? A single camera located in the rear view mirror looks like a sensible option, which I've been talking about for five years.

We can see the requirements for occupant monitoring. The 2026 test protocols for DMS are likely to be published soon, and will be worth up to 25 points. Cheap #visual #distraction algorithms look set to be replaced with complex requirements for both visual and #cognitivedistraction. Euro NCAP is an organization focused on saving lives, so out goes "box-ticking" and in comes an emphasis in the cabin towards understanding human behavior as it applies to crash risk. #Humanfactors expertise is about to become critical, which I've also been talking about for five years.

OEMs have mostly been focused on compliance for #GSR, which lulled them into the cheap and infuriating DMS path, without paying attention to what was happening with NCAP. The 2026 protocols won't impact GSR at all, but the consequence for OEMs looks set to be a lot of models losing the coveted 5* rating.

How much potential revenue could be expected from the expansion?

RNS July 2022

Preliminary activities for Tissue Regenix's Phase 2 expansion are due to start in the second half of 2024, with completion expected in 2025. The Phase 2 expansion will provide the Group with additional cleanrooms, operational capacity and further office space. The Phase 2 expansion is funded by the current business plan and will provide Tissue Regenix with substantial additional capacity as the management team continue to drive sustainable growth and scale the business.

I can’t SEE anything negative but will need continued patience. Great things come to those who wait, that’s my line to the wife! 🤣

Wake me up when the discussions are over and the audited results show revenue of 5-10 million and a profitable company…..

🥱

Where is the bombardment we were promised?? Must have got lucky with the barmaid, thrown up with a dodgy two course meal or 10 pints! 😜

Let’s SEE the update 😂

When is the trading update? I had 15th August in my diary.

Anyone in the know??